Relinking Diagnosed But Untreated HCV Patients Back Into Care.

Clinical Trial Summary

Reintroduction of patients into a HCV infection care pathway after a positive chronic hepatitis C diagnosis by previous testing in our hospital who were lost in follow-up. Gaining insight in the possible reasons why patients are lost in follow-up after positive hepatitis C serology.

See also
Status	Clinical Trial	Phase
Completed	`NCT02487030` - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection	Phase 3
Active, not recruiting	`NCT05460130` - Implementing HCV Treatment for High-risk Populations in Austin, Texas	N/A
Completed	`NCT02220998` - Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection	Phase 3
Terminated	`NCT01052090` - Safety and Efficacy Study in Hepatitis C Patients With PHN121	Phase 1/Phase 2
Completed	`NCT02537379` - Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection	N/A
Recruiting	`NCT04156945` - Interventions to Curb Hepatitis C Reinfections Among Men Who Have Sex With Men	N/A
Terminated	`NCT02510300` - A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials
Withdrawn	`NCT04309734` - Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects	Phase 1/Phase 2
Active, not recruiting	`NCT04001608` - Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients	Phase 3
Completed	`NCT04112303` - Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis	Phase 3
Completed	`NCT02251717` - Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection	Phase 2
Recruiting	`NCT05092074` - Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection
Recruiting	`NCT04005248` - Prevalence of HCV in HIV-negative MSM	N/A
Completed	`NCT02249182` - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection	Phase 2
Completed	`NCT02939989` - Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study	Phase 3
Completed	`NCT01718145` - A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects	Phase 3
Completed	`NCT01482611` - A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382	Phase 1
Completed	`NCT00255177` - Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	Phase 2
Terminated	`NCT02600351` - Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies	Phase 3
Completed	`NCT04980157` - CARES-HCV: Promoting Screening Uptake Among Diverse Baby Boomers

NCT number	NCT05975216
Study type	Observational
Source	Universitair Ziekenhuis Brussel
Contact	Silke François, Dr.
Phone	+32 2 477
Email	silke.francois@uzbrussel.be
Status	Recruiting
Phase
Start date	July 6, 2023
Completion date	July 31, 2027

Relinking Diagnosed But Untreated HCV Patients Back Into Care. — Relink

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms